Roth Capital raised the firm's price target on Electrovaya to $10 from $7 and keeps a Buy rating on the shares. The commissioning of cell production at Electrovaya's Jamestown, NY, facility towards the end of calendar 2026 will likely be a transformational moment for the company, the analyst tells investors in a research note.